Department of Internal Medicine, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.
Department of Medicine, Center for Neurointestinal Health, Division of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Neurogastroenterol Motil. 2023 May;35(5):e14534. doi: 10.1111/nmo.14534. Epub 2023 Feb 5.
Gastrointestinal (GI)-specific anxiety has been identified as a treatment target in irritable bowel syndrome. However, GI-specific anxiety has been understudied in other GI functional/motility disorders. Among adults with gastroparesis, we aimed to: (1) initially validate a measure of GI-specific anxiety, the Visceral Sensitivity Index (VSI); and (2) evaluate the relationship between GI-specific anxiety and gastroparesis symptom severity and quality of life, compared to measures of anxiety, depression, and somatization.
Consecutive adult patients (N = 100) with gastroparesis presenting for initial consultation completed a series of self-report measures including the VSI. We conducted a confirmatory factor analysis of the VSI one-factor structure and tested internal consistency and convergent validity. We then performed hierarchical linear regression analyses to explore associations between VSI and gastroparesis symptom severity and overall quality of life.
Confirmatory factor analysis revealed that the original VSI one-factor structure overall fit well [χ (90) = 220.1, p < 0.0001; SRMR = 0.08; RMSEA = 0.12; CFI = 0.96]. The VSI also had excellent internal consistency (α = 0.99) and convergent validity (r = 0.29-0.56; all p < 0.01). Higher GI-specific anxiety was significantly associated with greater gastroparesis symptom severity, including nausea/vomiting, fullness/satiety, and upper abdominal pain scores beyond depression, anxiety, or somatization (all p = <0.01-0.01). Additionally, higher GI-specific anxiety was significantly associated with lower mental health-related quality of life, beyond gastroparesis symptom severity, depression, anxiety, or somatization (p = 0.01).
CONCLUSIONS & INFERENCES: The VSI is an adequate measure of GI-specific anxiety in patients with gastroparesis. Higher GI-specific anxiety was associated with increased patient-reported gastroparesis symptom severity and decreased quality of life, beyond depression/anxiety.
胃肠道(GI)特异性焦虑已被确定为肠易激综合征的治疗靶点。然而,其他胃肠道功能/运动障碍中对 GI 特异性焦虑的研究较少。在患有胃轻瘫的成年人中,我们旨在:(1)最初验证一种胃肠道特异性焦虑的测量方法,即内脏敏感性指数(VSI);(2)与焦虑、抑郁和躯体化测量相比,评估胃肠道特异性焦虑与胃轻瘫症状严重程度和生活质量之间的关系。
连续就诊的成年胃轻瘫患者(N=100)完成了一系列自我报告的测量,包括 VSI。我们对 VSI 的单因素结构进行了验证性因素分析,并测试了内部一致性和收敛效度。然后,我们进行了分层线性回归分析,以探讨 VSI 与胃轻瘫症状严重程度和整体生活质量之间的关系。
验证性因素分析显示,原始 VSI 单因素结构总体拟合良好[χ(90)=220.1,p<0.0001;SRMR=0.08;RMSEA=0.12;CFI=0.96]。VSI 还具有极好的内部一致性(α=0.99)和收敛效度(r=0.29-0.56;所有 p<0.01)。较高的胃肠道特异性焦虑与胃轻瘫症状的严重程度显著相关,包括恶心/呕吐、饱腹感/饱胀感和上腹痛评分,超过了抑郁、焦虑或躯体化(所有 p<0.01-0.01)。此外,较高的胃肠道特异性焦虑与心理健康相关的生活质量显著相关,超过了胃轻瘫症状的严重程度、抑郁、焦虑或躯体化(p=0.01)。
VSI 是胃轻瘫患者胃肠道特异性焦虑的一个合适的测量方法。较高的胃肠道特异性焦虑与患者报告的胃轻瘫症状严重程度增加和生活质量下降有关,超过了抑郁/焦虑。